Business
Lilly's RNA partner Rznomics joins Lilly Gateway Labs
South Korea-based Rznomics Inc. (KOSDAQ: 476830) has joined Lilly Gateway Labs in San Diego, deepening a relationship with Eli Lilly and Company that began...
Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m
Alvotech (Nasdaq: ALVO) has licensed US and Asian commercialization rights for two biosimilar candidates — AVT34, a proposed biosimilar to durvalumab...
VectorBuilder, Lir apply AI to optimize AAV capsids for manufacturing
Chicago-based VectorBuilder and Ireland-based Lir Therapeutics have announced a joint platform collaboration to engineer adeno-associated virus (AAV)...
METiS, WestVac team up on AI-designed personalized mRNA cancer vaccines
METiS TechBio (HKEX: 7666) and China-based WestVac Biopharma have signed a strategic cooperation framework agreement to jointly develop personalized mRNA...
Ambros lands USD 150m financing in Werewolf reverse merger to fund neridronate Phase III
San Diego-based Ambros Therapeutics is merging with Waltham, Massachusetts-based Werewolf Therapeutics (Nasdaq: HOWL) in an all-stock transaction, with a...
Gossamer secures up to USD 250m to fund seralutinib through uncertain FDA path
San Diego-based Gossamer Bio (Nasdaq: GOSS) announced a structured private placement of up to USD 250 million, with USD 150 million in committed capital,...
Bristol Myers Squibb taps Chai Discovery's generative AI for antibody design across portfolio
San Francisco-based Chai Discovery and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to apply Chai's generative AI antibody discovery...
Ipsen closes USD 450m deal for Kartos and myelofibrosis asset navtemadlin
Ipsen (Euronext: IPN) has completed its acquisition of Kartos Therapeutics, the Redwood City, California-based clinical-stage company whose sole disclosed...
Hansa aims for secondary US listing ahead of FDA decision on kidney transplant therapy
Sweden-based Hansa Biopharma AB (Nasdaq Stockholm: HNSA), a commercial-stage immunology company with an EU-approved enzyme therapy and a pending US FDA...
Simcere takes on Beyfortus with China rights deal for long-acting RSV antibody
Simcere Pharmaceutical Group (HKEX: 2096) has secured exclusive commercialization rights in Greater China for kulaiweibai monoclonal antibody, a...
Amylyx ups fundraising target to USD 500m after avexitide's Phase III win in hypoglycemia
Cambridge, Massachusetts-based Amylyx Pharmaceuticals (Nasdaq: AMLX) announced the pricing of an upsized underwritten public offering of common stock,...
Lupin expands presbyopia footprint with EUR 75m Yuvezzi licensing deal across Europe
Lupin Limited (BSE: 500257, NSE: LUPIN) and Tenpoint Therapeutics Holding Limited have announced an exclusive licensing agreement granting Lupin's European...
UroGen takes first step beyond urothelial cancer with IntraGel deal
UroGen Pharma (Nasdaq: URGN) has signed a collaboration and equity investment agreement with Israel-based IntraGel Therapeutics, committing up to USD 7...
Amgen exits TScan TCR discovery collaboration tied to over USD 500m in milestones
Amgen has notified TScan Therapeutics (Nasdaq: TCRX) of its election to terminate the research collaboration and license agreement the two companies entered...
Kynexis takes Series A to EUR 97 million as Novartis backs schizophrenia cognition drug
Netherlands-based Kynexis announced the closing of a EUR 40 million (USD 45 million) extension to its Series A, bringing total Series A financing to EUR 97...
The AllSci Brief
Free, systematic R&D and deal news. Daily.